[
  {
    "ts": null,
    "headline": "Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026",
    "summary": "They could grow into their valuation over the next few years.",
    "url": "https://finnhub.io/api/news?id=1e1c4d3a55dddb444f4a0459ce51f911302b58bee27c5a34aa69e325d0b5e86a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765561380,
      "headline": "Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026",
      "id": 137770379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "They could grow into their valuation over the next few years.",
      "url": "https://finnhub.io/api/news?id=1e1c4d3a55dddb444f4a0459ce51f911302b58bee27c5a34aa69e325d0b5e86a"
    }
  },
  {
    "ts": null,
    "headline": "Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?",
    "summary": "BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.",
    "url": "https://finnhub.io/api/news?id=80d50ab2d8fac31f908832ea3f45722c7ad31bec6a44bd9ae59e296273fe16e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765553700,
      "headline": "Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?",
      "id": 137769422,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.",
      "url": "https://finnhub.io/api/news?id=80d50ab2d8fac31f908832ea3f45722c7ad31bec6a44bd9ae59e296273fe16e4"
    }
  },
  {
    "ts": null,
    "headline": "Does WINREVAIR’s CHMP-Backed Label Expansion Shift The Bull Case For Merck (MRK)?",
    "summary": "In early December 2025, Merck reported that the EMA’s Committee for Medicinal Products for Human Use recommended expanding WINREVAIR’s EU indication to cover adults with pulmonary arterial hypertension in WHO Functional Class II, III and IV, based on Phase 3 ZENITH data in high‑risk patients. This positive opinion, following recent U.S. label updates, strengthens WINREVAIR’s profile as a first‑in‑class activin signaling inhibitor and could broaden its clinical and commercial reach in severe...",
    "url": "https://finnhub.io/api/news?id=96920667718b32305de64486acd0aba3a38f6abd223f493e9105f42fa10e1d7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765552278,
      "headline": "Does WINREVAIR’s CHMP-Backed Label Expansion Shift The Bull Case For Merck (MRK)?",
      "id": 137769424,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "In early December 2025, Merck reported that the EMA’s Committee for Medicinal Products for Human Use recommended expanding WINREVAIR’s EU indication to cover adults with pulmonary arterial hypertension in WHO Functional Class II, III and IV, based on Phase 3 ZENITH data in high‑risk patients. This positive opinion, following recent U.S. label updates, strengthens WINREVAIR’s profile as a first‑in‑class activin signaling inhibitor and could broaden its clinical and commercial reach in severe...",
      "url": "https://finnhub.io/api/news?id=96920667718b32305de64486acd0aba3a38f6abd223f493e9105f42fa10e1d7e"
    }
  },
  {
    "ts": null,
    "headline": "Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?",
    "summary": "Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.",
    "url": "https://finnhub.io/api/news?id=e23bff1d294d5bd253d567c0746d26bc388f53ce2269d061f254a86ffd70b673",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765551780,
      "headline": "Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?",
      "id": 137769425,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.",
      "url": "https://finnhub.io/api/news?id=e23bff1d294d5bd253d567c0746d26bc388f53ce2269d061f254a86ffd70b673"
    }
  },
  {
    "ts": null,
    "headline": "Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)",
    "summary": "RAHWAY, N.J., December 12, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of an expanded indication for WINREVAIR™ (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II, III, and IV based on the Phase 3 ZENITH study. The cu",
    "url": "https://finnhub.io/api/news?id=bfb68282955700374e9e7e0db8ceb7dc03ab5414383781b092308e406c130007",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765547100,
      "headline": "Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)",
      "id": 137769427,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., December 12, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of an expanded indication for WINREVAIR™ (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II, III, and IV based on the Phase 3 ZENITH study. The cu",
      "url": "https://finnhub.io/api/news?id=bfb68282955700374e9e7e0db8ceb7dc03ab5414383781b092308e406c130007"
    }
  },
  {
    "ts": null,
    "headline": "2 Mega-Cap Stocks with Exciting Potential and 1 We Ignore",
    "summary": "Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.",
    "url": "https://finnhub.io/api/news?id=0b3a8e3d7e7696d2436f71f8ac60b466834a9cfcf766e2b7663ffd58a4e4ddee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765513925,
      "headline": "2 Mega-Cap Stocks with Exciting Potential and 1 We Ignore",
      "id": 137770380,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.",
      "url": "https://finnhub.io/api/news?id=0b3a8e3d7e7696d2436f71f8ac60b466834a9cfcf766e2b7663ffd58a4e4ddee"
    }
  }
]